Type Private COO Russell J. Cox | Traded as NASDAQ: JAZZ Revenue $340.9 million Q3 2015 | |
 | ||
Key people Bruce C. Cozadd(Chairman and CEO)Kathryn E. Falberg(CFO and Executive Vice President)Suzanne Sawochka Hooper(Executive Vice President and General Counsel)Russell J. Cox(Chief Commercial Officer) and Executive Vice President) Stock price JAZZ (NASDAQ) US$ 133.04 +0.08 (+0.06%)9 Mar, 4:00 PM GMT-5 - Disclaimer CEO Bruce C Cozadd (Apr 2009–) Subsidiaries Celator Pharmaceuticals Inc. Profiles | ||
Jazz pharmaceuticals breaks ground on new manufacturing and development facility in ireland
Jazz Pharmaceuticals PLC (a merger of Jazz Pharmaceuticals and Azur Pharma PLC) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug, Xyrem (Sodium Oxybate - another term for the identical substance more commonly referred to as GHB Gamma Hydroxy Butrate).
Contents
- Jazz pharmaceuticals breaks ground on new manufacturing and development facility in ireland
- A g capital s kramer says biotech company jazz pharmaceuticals has a bright future
- 2010
- 2011
- 2012
- 2014
- 2016
- Acquisition history
- Products
- References
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
A g capital s kramer says biotech company jazz pharmaceuticals has a bright future
2010
On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia In the following December, a new patent was issued for Sodium Oxybate
2011
On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge
2012
On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments In September the company successfully sold its Women's Health business to Meda for $95 million In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia
2014
In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion
2016
In May, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its largest acqusition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):